Beyond “Garbage In, Garbage Out”: Why AI in Biotech Demands a Fundamental Shift in Biological Data Quality
Generative artificial intelligence and foundation models applied to biology promise to drastically accelerate early-stage drug discovery. Yet, despite immense computational capacity and the proliferation of in silico platforms, the global clinical attrition rate in Phase II trials remains stuck near 70% with very few cases. The root cause of this persistent gap is not algorithmic



